{"groups":[{"description":"Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nBinimetinib: Given PO","id":"FG000","title":"Treatment (Binimetinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Never started threapy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"29"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Alternative therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Z1A, patients had to have a tumor harboring a codon 12, 13, or 61 NRAS-mutation.","recruitmentDetails":"Subprotocol Z1A was activated on May 31, 2016. A total of 114 patients were assigned to this arm after screening, all from screening cohort. Of the 114 patients, 53 patients were enrolled to arm Z1A in the period from May 31, 2016 and June 7, 2018."}